A Single-Sequence, Open-Label, 2-Period Crossover Trial to Evaluate the Effect of the Potent Cytochrome P-450 3A4 Inhibitor Itraconazole on the Pharmacokinetics of TAK-954 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
Price : $35 *
At a glance
- Drugs TD 8954 (Primary) ; Itraconazole
- Indications Gastrointestinal motility disorders
- Focus Pharmacokinetics
- Sponsors Takeda
- 27 Nov 2017 Status changed from active, no longer recruiting to completed.
- 17 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2017 New trial record